Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
Status:
Withdrawn
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and efficacy of administering sorafenib concurrent with
yttrium-90 radioembolization to patients with advanced hepatocellular cancer.